{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:23:07Z","timestamp":1770272587840,"version":"3.49.0"},"reference-count":74,"publisher":"Portland Press Ltd.","issue":"18","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 CA243542"],"award-info":[{"award-number":["R01 CA243542"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54-HG008097"],"award-info":[{"award-number":["U54-HG008097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs were screened for mitigators of VEGFRi-induced EC dysfunction and validated in primary aortic ECs, mice, and canine cancer patients. VEGFRi treatment significantly raised systolic blood pressure (SBP) and increased markers of endothelial and renal dysfunction in mice and canine cancer patients. \u03b1-Adrenergic-antagonists were identified as drugs that most oppose the VEGFRi proteomic signature. Doxazosin, one such \u03b1-antagonist, prevented EC dysfunction in murine, canine, and human aortic ECs. In mice with sorafenib-induced-hypertension, doxazosin mitigated EC dysfunction but not hypertension or glomerular endotheliosis, while lisinopril mitigated hypertension and glomerular endotheliosis without impacting EC function. Hence, reversing EC dysfunction was insufficient to mitigate VEGFRi-induced-hypertension in this mouse model. Canine cancer patients with VEGFRi-induced-hypertension were randomized to doxazosin or lisinopril and both agents significantly decreased SBP. The canine clinical trial supports safety and efficacy of doxazosin and lisinopril as antihypertensives for VEGFRi-induced-hypertension and the potential of trials in canines with spontaneous cancer to accelerate translation. The overall findings demonstrate the utility of phosphoproteomics to identify EC-protective agents to mitigate cardio-oncology side effects.<\/jats:p>","DOI":"10.1042\/cs20240537","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T10:37:54Z","timestamp":1726483074000},"page":"1131-1150","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors"],"prefix":"10.1042","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-0056","authenticated-orcid":false,"given":"Nicholas\u00a0D.","family":"Camarda","sequence":"first","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."},{"name":"2Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Lu","sequence":"additional","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn\u00a0M.","family":"Meola","sequence":"additional","affiliation":[{"name":"3Tufts Cummings School of Veterinary Medicine, North Grafton, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua\u00a0J.","family":"Man","sequence":"additional","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."},{"name":"2Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyuan","family":"Song","sequence":"additional","affiliation":[{"name":"4Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard\u00a0J.","family":"Travers","sequence":"additional","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."},{"name":"5Division of Hematology Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine\u00a0E.","family":"Lopez","sequence":"additional","affiliation":[{"name":"3Tufts Cummings School of Veterinary Medicine, North Grafton, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah\u00a0N.","family":"Powers","sequence":"additional","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malvina","family":"Papanastasiou","sequence":"additional","affiliation":[{"name":"6Broad Institute, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine\u00a0C.","family":"DeRuff","sequence":"additional","affiliation":[{"name":"6Broad Institute, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Mullahoo","sequence":"additional","affiliation":[{"name":"6Broad Institute, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn\u00a0B.","family":"Egri","sequence":"additional","affiliation":[{"name":"6Broad Institute, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree","family":"Davison","sequence":"additional","affiliation":[{"name":"6Broad Institute, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"4Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott\u00a0T.","family":"Eblen","sequence":"additional","affiliation":[{"name":"7Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Buchsbaum","sequence":"additional","affiliation":[{"name":"5Division of Hematology Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon\u00a0S.","family":"Huggins","sequence":"additional","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."},{"name":"8Division of Cardiology, Tufts Medical Center, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl\u00a0A.","family":"London","sequence":"additional","affiliation":[{"name":"3Tufts Cummings School of Veterinary Medicine, North Grafton, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob\u00a0D.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"6Broad Institute, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenica\u00a0N.","family":"Upshaw","sequence":"additional","affiliation":[{"name":"8Division of Cardiology, Tufts Medical Center, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky\u00a0K.","family":"Yang","sequence":"additional","affiliation":[{"name":"3Tufts Cummings School of Veterinary Medicine, North Grafton, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris\u00a0Z.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"1Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, U.S.A."},{"name":"2Genetics, Molecular, and Cellular Biology Program, Tufts Graduate School of Biomedical Sciences, Boston, MA, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"18","key":"2024091610371705600_B1","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.3390\/ijms20184411","article-title":"Vascular endothelial cell biology: an update","volume":"20","author":"Kruger-Genge","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"2024091610371705600_B2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2024091610371705600_B3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"2024091610371705600_B4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"2024091610371705600_B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"2024091610371705600_B6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"2024091610371705600_B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail."},{"key":"2024091610371705600_B8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"2024091610371705600_B9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","article-title":"Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors","volume":"104","author":"Dobbin","year":"2018","journal-title":"Heart"},{"key":"2024091610371705600_B10","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"2024091610371705600_B11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jvim.13951","article-title":"Effects of toceranib phosphate on systolic blood pressure and proteinuria in dogs","volume":"30","author":"Tjostheim","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"2024091610371705600_B12","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1038\/s41598-018-27377-2","article-title":"Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci. Rep."},{"key":"2024091610371705600_B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors","volume":"114","author":"Shah","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"2024091610371705600_B14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2024091610371705600_B15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.121.318051","article-title":"Hypertension and prohypertensive antineoplastic therapies in cancer patients","volume":"128","author":"van Dorst","year":"2021","journal-title":"Circ. Res."},{"key":"2024091610371705600_B16","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2024091610371705600_B17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J. Am. Soc. Hypertens."},{"key":"2024091610371705600_B18","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1042\/CS20200308","article-title":"Vascular toxicity associated with anti-angiogenic drugs","volume":"134","author":"Neves","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"2024091610371705600_B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199700531-00003","article-title":"Endothelial function. General considerations","volume":"53","author":"Haller","year":"1997","journal-title":"Drugs"},{"key":"2024091610371705600_B20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction: testing and clinical relevance","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation"},{"key":"2024091610371705600_B21","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1172\/JCI81067","article-title":"P2Y(2) and Gq\/G(1)(1) control blood pressure by mediating endothelial mechanotransduction","volume":"125","author":"Wang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2024091610371705600_B22","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/HYPERTENSIONAHA.114.03837","article-title":"Nitric oxide inhibition of endothelin-1 release in the vasculature: in vivo relevance of in vitro findings","volume":"64","author":"Rapoport","year":"2014","journal-title":"Hypertension"},{"key":"2024091610371705600_B23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"key":"2024091610371705600_B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ars.2013.5244","article-title":"Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress","volume":"20","author":"Lankhorst","year":"2014","journal-title":"Antioxid Redox Signal."},{"key":"2024091610371705600_B25","doi-asserted-by":"publisher","first-page":"R230","DOI":"10.1152\/ajpregu.00373.2015","article-title":"Endothelin-1 and antiangiogenesis","volume":"310","author":"Lankhorst","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2024091610371705600_B26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"2024091610371705600_B27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/diagnostics11040640","article-title":"Nephrotoxicity of anti-angiogenic therapies","volume":"11","author":"Van Wynsberghe","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2024091610371705600_B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.116.07618","article-title":"Mechanisms of hypertension and renal injury during vascular endothelial growth factor signaling inhibition","volume":"68","author":"van den Meiracker","year":"2016","journal-title":"Hypertension"},{"key":"2024091610371705600_B29","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"2024091610371705600_B30","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1681\/ASN.2007020255","article-title":"The glomerular injury of preeclampsia","volume":"18","author":"Stillman","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"2024091610371705600_B31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"2024091610371705600_B32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17512433.2020.1734450","article-title":"Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2024091610371705600_B33","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat. Med."},{"key":"2024091610371705600_B34","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1093\/cvr\/cvac007","article-title":"Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular ageing","volume":"118","author":"Ibarrola","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"2024091610371705600_B35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","article-title":"Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care","volume":"36","author":"Lankheet","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"2024091610371705600_B36","doi-asserted-by":"publisher","first-page":"e0167906","DOI":"10.1371\/journal.pone.0167906","article-title":"Phase I\/II Trial of Sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer","volume":"11","author":"Ferrario","year":"2016","journal-title":"PloS ONE"},{"key":"2024091610371705600_B37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/1746-6148-9-190","article-title":"Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose","volume":"9","author":"Bernabe","year":"2013","journal-title":"BMC Vet Res."},{"key":"2024091610371705600_B38","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1128\/MCB.06327-11","article-title":"Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion","volume":"32","author":"Al-Ayoubi","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"2024091610371705600_B39","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/bloodadvances.2018020396","article-title":"A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML","volume":"2","author":"Gopal","year":"2018","journal-title":"Blood Adv."},{"key":"2024091610371705600_B40","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1074\/mcp.M116.058354","article-title":"Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes","volume":"15","author":"Abelin","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"2024091610371705600_B41","doi-asserted-by":"publisher","first-page":"424e7","DOI":"10.1016\/j.cels.2018.03.012","article-title":"A library of phosphoproteomic and chromatin signatures for characterizing cellular responses to drug perturbations","volume":"6","author":"Litichevskiy","year":"2018","journal-title":"Cell Syst."},{"key":"2024091610371705600_B42","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1681\/ASN.2013030291","article-title":"Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor","volume":"25","author":"Holwerda","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"2024091610371705600_B43","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/j.1523-1755.2005.00316.x","article-title":"Preeclampsia: a renal perspective","volume":"67","author":"Karumanchi","year":"2005","journal-title":"Kidney Int."},{"key":"2024091610371705600_B44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"issue":"2","key":"2024091610371705600_B45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/ph16020295","article-title":"Mechanism underlying triple VEGFR inhibitor tivozanib-induced hypertension in mice model","volume":"16","author":"Alanazi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024091610371705600_B46","doi-asserted-by":"publisher","first-page":"H692","DOI":"10.1152\/ajpheart.00172.2015","article-title":"The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity","volume":"309","author":"Bordun","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2024091610371705600_B47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40959-020-00064-w","article-title":"The hypertensive effect of sorafenib is abolished by sildenafil","volume":"6","author":"Dabire","year":"2020","journal-title":"Cardiooncology"},{"key":"2024091610371705600_B48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"2024091610371705600_B49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.111.182220","article-title":"Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress","volume":"59","author":"Kappers","year":"2012","journal-title":"Hypertension"},{"key":"2024091610371705600_B50","doi-asserted-by":"publisher","first-page":"e91897","DOI":"10.1371\/journal.pone.0091897","article-title":"SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice","volume":"9","author":"Amraoui","year":"2014","journal-title":"PloS ONE"},{"key":"2024091610371705600_B51","doi-asserted-by":"publisher","first-page":"694711","DOI":"10.3389\/fcvm.2021.694711","article-title":"Updates on anticancer therapy-mediated vascular toxicity and new horizons in therapeutic strategies","volume":"8","author":"Hsu","year":"2021","journal-title":"Front Cardiovasc. Med."},{"key":"2024091610371705600_B52","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2024091610371705600_B53","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1440-1681.2012.05699.x","article-title":"Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib","volume":"39","author":"Nagasawa","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2024091610371705600_B54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2165\/00003495-198835050-00003","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension","volume":"35","author":"Young","year":"1988","journal-title":"Drugs"},{"key":"2024091610371705600_B55","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/clc.4960131104","article-title":"Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism","volume":"13","author":"Nash","year":"1990","journal-title":"Clin. Cardiol."},{"key":"2024091610371705600_B56","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/ijtm1030021","article-title":"A systematic review on the role of adrenergic receptors in angiogenesis regulation in health and disease","volume":"1","author":"Xanthopoulos","year":"2021","journal-title":"Int. J. Transl. Med."},{"key":"2024091610371705600_B57","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1097\/00005344-200111000-00016","article-title":"Endothelial Adrenoceptors","volume":"38","author":"Vanhoutte","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2024091610371705600_B58","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0895-7061(97)00265-3","article-title":"Effect of doxazosin on endothelial dysfunction in hypercholesterolemic\/antioxidant-deficient rats","volume":"10","author":"Raij","year":"1997","journal-title":"Am. J. Hypertens."},{"key":"2024091610371705600_B59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1291\/hypres.25.5","article-title":"Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation","volume":"25","author":"Komai","year":"2002","journal-title":"Hypertens. Res."},{"key":"2024091610371705600_B60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2014.11.010","article-title":"Etiology of angiogenesis inhibition-related hypertension","volume":"21","author":"Lankhorst","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"2024091610371705600_B61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrneph.2013.251","article-title":"The effect of RAAS blockade on the progression of diabetic nephropathy","volume":"10","author":"Roscioni","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"2024091610371705600_B62","doi-asserted-by":"publisher","first-page":"e0143455","DOI":"10.1371\/journal.pone.0143455","article-title":"Tissue specificity of human angiotensin i-converting enzyme","volume":"10","author":"Kryukova","year":"2015","journal-title":"PloS ONE"},{"key":"2024091610371705600_B63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrneph.2012.281","article-title":"Improving the efficacy of RAAS blockade in patients with chronic kidney disease","volume":"9","author":"Lambers Heerspink","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"2024091610371705600_B64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/HYPERTENSIONAHA.109.132274","article-title":"Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors?","volume":"54","author":"Granger","year":"2009","journal-title":"Hypertension"},{"key":"2024091610371705600_B65","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1152\/ajpregu.90972.2008","article-title":"Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats","volume":"297","author":"Gu","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2024091610371705600_B66","first-page":"436","article-title":"Pharmacologic characteristics of bladder micturition function in anesthetized mice","volume":"60","author":"Zhou","year":"2010","journal-title":"Comp. Med."},{"key":"2024091610371705600_B67","first-page":"46","article-title":"Impact of \u03b1-adrenoceptor antagonists on prostate cancer development, progression and prevention","volume":"7","author":"Wade","year":"2019","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"2024091610371705600_B68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11906-018-0871-1","article-title":"Management of VEGF-targeted therapy-induced hypertension","volume":"20","author":"Caletti","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"2024091610371705600_B69","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2024091610371705600_B70","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"2024091610371705600_B71","doi-asserted-by":"publisher","first-page":"298","DOI":"10.4081\/oncol.2016.298","article-title":"Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma","volume":"10","author":"Derosa","year":"2016","journal-title":"Oncol. Rev."},{"key":"2024091610371705600_B72","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2024091610371705600_B73","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"2024091610371705600_B74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaccao.2019.08.012","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"JACC: Cardio. Oncol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/138\/18\/1131\/961031\/cs-2024-0537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/138\/18\/1131\/961031\/cs-2024-0537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T10:38:01Z","timestamp":1726483081000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/138\/18\/1131\/234922\/Identifying-mitigating-strategies-for-endothelial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":74,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20240537","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,9]]}}}